Form 8-K - Current report:
SEC Accession No. 0001193125-24-253143
Filing Date
2024-11-07
Accepted
2024-11-07 16:27:03
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d841992d8k.htm   iXBRL 8-K 24848
2 EX-99.1 d841992dex991.htm EX-99.1 53244
6 GRAPHIC g841992g1107030930388.jpg GRAPHIC 2585
  Complete submission text file 0001193125-24-253143.txt   215002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20241107.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20241107_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20241107_pre.xml EX-101.PRE 11268
17 EXTRACTED XBRL INSTANCE DOCUMENT d841992d8k_htm.xml XML 3640
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 241436262
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)